Bristol-Myers Squibb Co BMY

Morningstar Rating

Unlock

$53.96 +0.36 (0.67%)

View Full Chart

As of Oct 4, 2024 11:00pm Delayed Price Closed

Company Report

View Archive

Bristol's Growing Portfolio and Pipeline Partly Offset Headwinds From Generic Competition

Karen Andersen Sep 27, 2024

Adept at partnerships and acquisitions, Bristol-Myers Squibb has built a strong portfolio of drugs and a robust pipeline. This strategy is seen with its large acquisition of Celgene, which netted the firm an excellent pipeline and a strong entrenchment in blood cancer. More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat.

Read Full Report

Price vs Fair Value

View History

BMY is trading at a 214% premium.

Price

$53.96

Oct 4, 2024

Fair Value

$44.00

Oct 26, 2023

Uncertainty

Medium

1-Star Price: $35.14
5-Star Price: $25.90
Economic Moat: Pwlq
Capital Allocation: Nzdvklsfn

Bulls Say, Bears Say

Bulls

Bristol is launching innovative drugs in cardiology and neurology, which should have strong sales trajectories given the high unmet medical need.

Bears

The acquisition of Celgene came shortly before generic competition for Celgene's cancer drug Revlimid in 2022, setting up a major growth obstacle over several years, given the planned staggered generic entry.

News

View All

Trading Information

Previous Close Price: $53.60
Day Range: $53.30–54.01
52-Week Range: $39.35–57.65
Bid/Ask: $53.51 / $53.88
Market Cap: $109.40 Bil
Volume/Avg: 12.8 Mil / 13.8 Mil

Key Statistics

Price/Earnings (Normalized): 7.04
Price/Sales: 2.36
Dividend Yield (Trailing): 4.45%
Dividend Yield (Forward): 4.45%
Total Yield: 8.10%

Company Profile

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Sector: Healthcare
Industry: Drug Manufacturers - General
Stock Style Box: Large Value
Total Number of Employees: 34,100
Website: https://www.bms.com

Competitors

Valuation

Metric	BMY	LLY	PFE
Price/Earnings (Normalized)	7.04	79.49	20.96
Price/Book Value	6.43	58.90	1.85
Price/Sales	2.36	20.60	2.90
Price/Cash Flow	7.24	79.87	21.18

Price/Earnings

BMY

LLY

PFE

Financial Strength

Metric	BMY	LLY	PFE
Quick Ratio	0.94	0.61	0.51
Current Ratio	1.16	1.11	0.86
Interest Coverage	−3.16	15.08	−0.88

Quick Ratio

BMY

LLY

PFE

Profitability

Metric	BMY	LLY	PFE
Return on Assets (Normalized)	3.04%	13.15%	3.50%
Return on Equity (Normalized)	11.63%	69.16%	8.28%
Return on Invested Capital (Normalized)	5.77%	23.97%	5.39%

Return on Assets

BMY

LLY

PFE

Drug Manufacturers - General Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Eli Lilly and Co LLY	Xkxfwtxqw	Tvjqn	$798.8 Bil
Johnson & Johnson JNJ	Htxdsbvq	Svn	$385.9 Bil
AbbVie Inc ABBV	Mvlvjxqs	Qhgt	$343.2 Bil
Merck & Co Inc MRK	Vmlfgmvn	Hynl	$278.2 Bil
Roche Holding AG ADR RHHBY	Xdtlxvsvm	Thlrw	$244.4 Bil
AstraZeneca PLC ADR AZN	Jcwckwqjc	Xrvf	$238.9 Bil
Novartis AG ADR NVS	Ffcjljlbb	Csyk	$232.2 Bil
Amgen Inc AMGN	Bmplrjhcx	Rmyy	$171.8 Bil
Pfizer Inc PFE	Kjpfkln	Jzyqk	$162.0 Bil
Sanofi SA ADR SNY	Zzrxvsxf	Ght	$140.7 Bil

Bristol-Myers Squibb Co BMY

Company Report

Bristol's Growing Portfolio and Pipeline Partly Offset Headwinds From Generic Competition

Price vs Fair Value

Bulls Say, Bears Say

Bulls

Bears

News

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting

Trending: Bristol Myers Gets FDA Approval for Schizophrenia Drug

Bristol-Myers Squibb stock jumps on schizophrenia drug approval

2seventy, Bristol Myers Drop Abecma Study in Newly Diagnosed Patients

Trading Information

Key Statistics

Company Profile

Competitors

Valuation

Financial Strength

Profitability

Drug Manufacturers - General Industry Comparables

Sponsor Center

How we make money

How we use your personal data

How we approach editorial content

What We Do

Company

Get Help